Close Menu

stock offering

The cancer molecular diagnostics firm said it will use the proceeds from the offering to support its R&D activities and for general corporate purposes.

CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.

ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.

The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.

he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.

The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.

The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.

BD has also granted the offerings' underwriters an option to purchase up to an additional $450 million of common stock and depositary shares.

The firm said it will use the funds for general corporate purposes, which may include investment and acquisitions, working capital, and debt repayment.

The firm said it would use the funds for general corporate purposes, including potential future acquisitions, capital expenditures, and investments or loans.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.